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Abstract
Background: The available evidence regarding the possible effects of resveratrol on liver function 
is inconsistent. Therefore, the present meta-analysis was performed to investigate the overall 
effects of resveratrol supplementation on liver enzymes in adults.
Methods: A systematic and comprehensive search of the online medical databases including 
PubMed, Scupos, Web of Science and Cochran Library was performed up to February 2020. All 
RCTs using resveratrol supplements in adults were included in this systematic review and meta-
analysis. The overall effect was presented as weighted mean difference (WMD) and 95% 
confidence interval (CI) in a random-effects meta-analysis model.
Results: Finally, 15 randomized trials including 714 participants were selected for the present 
meta-analysis. Pooled analysis did not show any significant changes in alanine aminotransferase 
(ALT) (WMD: 0 IU/L, 95% CI: -3.17 to 3.17, p = 0.99; I2 = 74.2%), aspartate aminotransferase 
(AST) (WMD: -2.40 IU/L, 95% CI: -5.45 to 0.65, p = 0.11; I2 = 82.9%), gamma-glutamyl 
transferase (GGT) (WMD: -1.26 IU/L, 95% CI: -4.64 to 2.13, p = 0.64; I2 = 23.7%), alkaline 
phosphatase (ALP) (WMD: 3.80 IU/L, 95% CI: -4.65 to 12.25, p = 0.37; I2 = 29.9%) and bilirubin 
(WMD: 0.13 IU/L, 95% CI: -0.43 to 0.17, p = 0.39; I2 = 8.9%) after supplementation with 
resveratrol.
Conclusion: Overall in our study resveratrol does not effect on liver enzyme levels significantly, 
but subgroup analysis indicates that these results may be influenced by resveratrol dose, duration 
of the study and population status, so future high-quality studies are necessary to get definitive 
results.
Keywords: Resveratrol, Alanine aminotransferase, Aspartate aminotransferase, Liver enzyme, 
Systematic review, Meta-analysis
What’s already known about this topic?
• Some previous studies showed the beneficial effects of resveratrol.
• There have been no meta-analysis to summarize the effect of resveratrol on liver enzymes in 
adults.
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• This study is the first systematic review and meta-analysis that was designed to evaluate the 
effect of resveratrol on liver enzymes in adults.
• The present study suggests that resveratrol supplementation does not effect on liver enzyme 
levels significantly.
• However, subgroup analysis indicates that these results may be influenced by resveratrol dose, 
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Introduction 
Over the last several decades, liver diseases have rapidly risen to become one of the global public 
health problems 1. In 2010, rather than 2 million deaths happened due to the chief liver disorders 
including acute hepatitis, cirrhosis, and liver cancer, which were responsible for about 4% of all of 
global mortality 2. Therefore increasing the prevalence of liver diseases in the world increases the 
overall cost of health care systems and decreases the quality of life 3 . The pathogenesis of the 
liver disease is complex, causes of liver disease include genetic and environmental factors such as 
viral infections, excessive alcohol consumption, and obesity 4. There are various drug therapies 
available for the treatment of liver disease 5, but in recent years, along with these pharmacologic 
strategies, the use of herbal remedies 6 and medicine has become more prosperous due to fewer 
side effects and lower costs than chemical drugs 7. Resveratrol (3,5,4′‐trihydroxystilbene) is one of 
the most favourite acetylbene-derived phytochemicals belonging to the polyphenol strain. Rich 
dietary sources of resveratrol include peanuts, cocoa, red grapes, red and white wine, and various 
berries 8. Numerous experimental studies have shown the protective effects of resveratrol in the 
prevention and treatment of various diseases including cancer 9, Alzheimer 10, viral infections 11, 
cardiovascular 12 and inflammatory disease 13. The major mechanisms of the protective effects of 
resveratrol are due to its antioxidant 14, anti-inflammatory 15, anti-apoptotic 16 and immune- 
activities 17. Recently, several studies have reported the beneficial effects of resveratrol in 
prevention of fat accumulation 18, reduction of liver enzymes 19, lipid peroxidation and oxidative 
stress in hepatocytes 20, but in another study resveratrol had no significant effect on liver enzymes 
21. Due to the increasing prevalence of liver disease in communities and inconclusive evidence of 
the efficacy of resveratrol in the treatment of liver dysfunction, we conducted a systematic review 
and meta-analysis of all available randomized controlled trials (RCTs) to investigate the influence 
of resveratrol on liver function.
Methods
This systematic review and meta-analysis was performed in accordance with PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses) statement guidelines 22 and  the 
PICOS model for the definition of the inclusion criteria: P (Population): “adults”, I (Intervention): 
“impact of the of resveratrol supplementation”, C (Comparators): “same conditions with control or 
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Search strategy
A systematic and comprehensive search of the online medical databases including PubMed, 
Scupos, Web of Science and Cochran Library was performed up to February 2020, using the 
following search terms in titles and abstracts to identify the potential interest articles: 
(“Resveratrol” OR “Vitis vinifera") AND "("Intervention Studies" OR "Intervention" OR 
"Controlled trial" OR "Randomized" OR "Randomised" OR "Random" OR "Randomly" OR 
"Placebo" OR "Assignment"). The search was conducted with no restriction on articles' language 
or time of publication. In addition, since that several studies examined the effect of resveratrol 
supplementation on liver function test as the secondary outcome, we did not use liver function test 
keywords. The complete search method is shown in supplementary Table 1. All reference lists of 
retrieved eligible papers and related reviews were also checked manually to avoid missing any 
relevant studies.
Study selection
First, electronic and manual search results were exported to End-Note software, version X8 
(Thomson Reuters) and duplicate publications were removed. Then, two investigators (M.D and 
A.GH) selected eligible articles, independently, by reading the title, abstract, and, where required, 
the full-text version of remaining publications. Finally, all human RCTs (either parallel or cross-
over designs) that examined the effects of resveratrol supplementation on liver function in adults 
(age ≥18 years old) were included. 
Studies were excluded if they (i) supplemented resveratrol in combination with any other drugs, 
minerals, or botanicals (unless a separate arm controlled the effect of the mixed substance); (ii) 
were publications with duplicate data; (iii) contained trials with follow up duration less than 4 
weeks; (iv) used red wine instead of resveratrol supplements; (v) did not have control group and 
(vi) were publications that did not report outcome measures at study baseline and end of 
intervention (or changes in outcome measures) or which examined the effects of resveratrol. 
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The following data were extracted from the full-text of included studies using a predesigned 
abstraction form as follows: first author's last name, publication year, location of the study, study 
design, target population, body mass index (BMI of participants), mean age, gender, total sample 
size, study duration, type of resveratrol, dose of resveratrol supplementation, and main results. 
When the data were reported at multiple measurements, only the outcomes at the end of the 
intervention were included in the analysis. Data extraction was conducted by two authors, 
independently (M. D and A.GH). Subsequently, full texts studies were assessed, and discrepancies 
were resolved through discussion with a third, independent researcher. In the case of multiple 
publications with duplicate/overlapped data for the same trial, we selected the publication with 
comprehensive and complete data.
Quality assessment of studies
We appraised the quality of relevant trials based on the Cochrane criteria 23, which is composed of 
the following ones: sequence generation sufficiency, allocation concealment, blinding, 
clarification of failures (imperfect outcome data) and selective outcome reporting. According to 
the Cochrane's Handbook, studies were ranked as low (L), or high risk of bias (H) or unclear (U) 
regarding each field.
Statistical analysis
All analyses were performed using STATA software version 12 (STATA corp, College Station, 
TX, USA). The mean difference (WMD) and the standard deviation (SD) of the alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), Gamma-glutamyl transferase (GGT), 
alkaline phosphatase (AL) and bilirubin between the intervention and control groups were applied 
to calculate overall effect size. The SD of the mean difference for not reported studies was 
calculated by the following formula: SD = square root [(SD pre-treatment) 2 + (SD post-treatment) 
2 – (2 × R × SD pretreatment × SD post-treatment)], where correlation coefficient (R) was 
considered as 0.5 24. To make sure that our meta-analysis is not sensitive to the selected correlation 
coefficient (R = 0.5), we used correlation coefficients (R) 0.2 and 0.8 for reporting all the analyses 
of body indices. Random-effects models were used to conduct all meta-analyses. The 
heterogeneity between studies was examined by the I-squared (I2) index. We carried out subgroup 
analysis based on dosage of resveratrol (≥ 1000 mg/day and < 1000 mg/day), study duration (> 12 
weeks and ≤ 12 weeks), study population (healthy and unhealthy), baseline BMI (≥ 30 and < 30), 
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Rather, sensitivity analyses were performed to explore the extent to which inferences might 
depend on a particular study or group of studies. We also evaluated publication bias by two formal 
tests, the Begg-adjusted rank correlation test and the Egger’s regression asymmetry test.
Results  
Search results and study selection
Briefly, the initial literature search provided 3560 articles from all the electronic reference 
databases, we removed 2204 duplicate articles. After screening the titles and abstracts of these 
articles 1320 abstracts were deemed to be potentially irrelevant for the meta-analysis. In the next 
step, full-text articles were carefully appraised, then twenty-one papers were excluded based on 
the full-text review. These exclusions were because of the following reasons: administered 
resveratrol in combination with other (n = 5), duplicate dataset (n = 6), not having placebo group 
(n = 3), studies that did not provide sufficient data for outcomes (n = 7). Finally, fifteen trials 25-39 
were included in this meta-analysis. Of these, all trials 25-39 reported the effect of resveratrol on 
ALT, twelve articles 25-30,32,33,36-39 on AST, seven articles 25,29,30,32,33,37,39 on GGT, four trials on 
ALP 26,32,37,39 and five trials 26,28,30,32,36 on bilirubin. The process of study identification is 
presented in Figure 1. 
Characteristics of the included studies
The main characteristics of eligible trials, which were performed in 2013 and 2018, are 
summarized in Table 1. These trials used parallel designs. Out of fifteen included studies, six 
studies performed in Europe 32-36,39, two in America 25,26, six studies in Asia 27,29-31,37,38 and one 
study in Australia 28. Participant's age ranged from 21 to 73 years. Six studies 25,28,31,34,35,39 were 
conducted exclusively on males, and nine 26,27,29,30,32,33,36-38 were performed on both genders. 
Resveratrol dose ranged from 100 to 3000 g/day, and intervention duration ranged from 4 to 52 
weeks. Included studies were carried-out in subjects with overweight and obese adults 26,33,35, 
T2DM 31,37-39, metabolic syndrome 34, non-alcoholic fatty liver (NAFLD) 27-30,32 and healthy 
volunteers 25,36. Also in two studies, the unit of measurement of the enzymes was mg / dl which 
was different from the other (IU/L), so we excluded them. In both studies, resveratrol significantly 
reduced the levels of some liver enzymes 40,41.
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Table 2 presents a quality assessment of included studies based on the Cochrane collaboration‘s 
risk of bias assessment tool 23. According to a random sequence generation, six studies were 
characterized by lack of information 26,32-34,38,39 and one study showed high risk of bias 25. Also, all 
studies provided sufficient data on allocation concealment and showed low risk of bias regarding 
blinding of participants and personnel, nonetheless most studies showed unclear risk of bias based 
on blinding of outcome assessment. However, all included studies showed low risk of bias 
according to incomplete outcome data except two studies 25,34. 
Effect of resveratrol supplementation on ALT
Overall, fifteen eligible studies 25-39, including a total of 714 participants (327 intervention, 342 
placebo), examined the effect of resveratrol supplementation on ALT. Combining their findings, 
based on the random effects model, we found that ALT was not affected by resveratrol 
supplementation (WMD: 0 IU/L, 95% CI: -3.17 to 3.17, p = 0.99), with a significant between-
study heterogeneity (I2 = 74.2%, p < .001; Figure 2). Subgroup analysis based on dosage (< 1000 
mg/day vs ≥ 1000 mg/day), (duration > 12-week vs duration ≤ 12 week), (baseline BMI < 30 vs 
baseline BMI ≥ 30), gender (Men and both), (age < 48y vs age ≥ 48y) Could not explain the 
source of heterogeneity, although supplementation of resveratrol with longer duration (> 12 week) 
(WMD: -2.96 IU/L, 95% CI: -12.68 to 6.76), and in subjects younger than 48 years (WMD: -3.66 
IU/L, 95% CI: -8.42 to 1.10), had a greater effect size then overall (Table 3). 
Effect of resveratrol supplementation on AST
Twelve articles 25-30,32,33,36-39, including a total of 614 subjects (313 intervention, 301 placebo), 
reported the effect of resveratrol consumption on AST. Pooled effect size did not show any 
significant effect of resveratrol supplementation on AST (WMD: -2.40 IU/L, 95% CI: -5.45 to 
0.65, p = 0.11), with a significant between-study heterogeneity (I2 = 82.9%, p < .001) (Figure 3). 
Subgroup analysis based on dosage (< 1000 mg/day ≥ 1000 mg/day), (duration > 12 week, 
duration ≤ 12 week), (baseline BMI < 30, baseline BMI ≥ 30), gender (Men, both) could not 
eliminate heterogeneity, although subgroup analysis based on age showed significant effects of 
resveratrol on AST in younger subjects (age < 48y) (WMD: -5.91 IU/L, 95% CI: -10 to -1.83), 
also the results revealed that resveratrol supplementation was more effective in longer periods (> 
12 week) (WMD: -11.78 IU/L, 95% CI: -42.75 to 19.19 ) and in non-obese individuals (WMD: -
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Effect of resveratrol supplementation on GGT
Seven articles 25,29,30,32,33,37,39, including a total of 394 subjects (198 intervention, 196 placebo), 
reported the effect of resveratrol consumption on GGT. Pooled effect size did not show any 
significant effect of resveratrol supplementation on GGT (WMD: -1.26 IU/L, 95% CI: -4.64 to 
2.13, p = 0.64) (Figure 4). Also between-study heterogeneity was not significant (I2 = 23.7%, p = 
0.248). Subgroup analysis based on duration and dosage showed a significant reduction of GGT in 
the subset of studies with ≤ 12 weeks’ duration (WMD: WMD: -2.64 IU/L, 95% CI: -4.08 to -
1.19) and dosage of < 1000 mg/day (WMD: -2.73 IU/L, 95% CI: -4.17 to -1.28). Also, additional 
subgroup analysis showed a significant decrease in GGT in younger subjects (age < 48y) (WMD: -
2.78 IU/L, 95% CI: -4.25 to -1.32) with baseline BMI< 30 (WMD: -2.64 IU/L, 95% CI: -4.08 to -
1.19) (Table 3).
Effect of resveratrol supplementation on ALP
Overall, four clinical trials 26,32,37,39, including a total of 148 subjects (81 intervention and 67 
placebo), reported the effect of resveratrol consumption on ALP. Pooled effect size did not show 
any significant effect of resveratrol supplementation on ALP (WMD: 3.80 IU/L, 95% CI: -4.65 to 
12.25, p = 0.37) (Figure 5). Also between-study heterogeneity was not significant (I2 = 29.9%, p 
=0.22). We could not perform subgroup analysis due to a lack of eligible studies. The sensitivity 
analysis showed that overall estimates were not affected by elimination of any individual study.
Effect of resveratrol supplementation on bilirubin 
 Five clinical trials 26,28,30,32,36, including a total of 208 subjects (120 intervention and 88 placebo), 
reported the effect of resveratrol consumption on bilirubin. Pooled effect size did not show any 
significant effect of resveratrol supplementation on bilirubin (WMD: 0.13 IU/L, 95% CI: -0.43 to 
0.17, p = 0.39) (Figure 6). Also between-study heterogeneity was not significant (I2 = 8.9%, p 
=0.35). We could not perform subgroup analysis due to lack of eligible studies. The sensitivity 
analysis showed that overall estimates were not affected by elimination of any individual study.
Sensitivity analysis 
The sensitivity analysis suggested that overall estimates for serum ALT, AST, GGT, ALP and 
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Publication bias
No evidence of publication bias was found for ALT (p= 0.24, Begg’s test and p= 0.06, Egger’s 
test), AST (p= 0.1, Begg’s test and p= 0.67, Egger’s test), GGT (p=0.055, Begg’s test and p=0.66, 
Egger’s test), ALP (p=0.62, Begg’s test and p= 0.83, Egger’s test) and bilirubin (p=0.34, Begg’s 
test and p= 0.39, Egger’s test).
Discussion
Despite the beneficial effects of plant on the health and treatment of numerous diseases, there are 
currently concerns about their potential useful or harmful effects on liver function. Resveratrol is 
one of the plants that is currently widely used for its antioxidant, anti-inflammatory and anti-
apoptotic effects 14-16 in liver disease. To the best of our knowledge, the present study is the first 
systematic review and meta-analysis of outcomes from fifteen RCTs on the efficacy of resveratrol 
supplementation on liver function.
The results of our meta-analysis did not show any significant changes in ALT, AST, GGT, ALP 
and bilirubin after supplementation with resveratrol, but subgroup analysis illustrate resveratrol 
had a greater effect size than the overall outcome in the longer term ( > 12 week  ) and younger 
subjects (age < 48y), but could not explain the source of significant between-study heterogeneity 
in the effects of resveratrol on ALT and AST.
Resveratrol is a type of natural plant polyphenol specifically present in red grapes, it has anti-
aging, anti-inflammatory, and that might be linked to chronic diseases and/or length of life in 
humans 42-45. Animal and human studies illustrated resveratrol supplementation has many benefits, 
including protection against cardiovascular disease and chronic inflammation by reducing LDL 
oxidation and platelet aggregation 46, improvement of insulin sensitivity 47,48 and dyslipidaemia 49, 
reduced systolic and diastolic blood pressure  50, promoting brain health and preventing 
neurological disorders such as Alzheimer's 51, however, the present results did not reveal the 
beneficial effect of resveratrol use on liver enzymes.
Previous studies regarding the effect of resveratrol supplementation on liver function have shown 
conflicting results. Similar to our study, two meta-analyzes showed that resveratrol consumption 
had no effect on ALT and AST levels 52,53. Heebøll et al. consistently demonstrated that 
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Faghihzadeh et al. reported that 12 weeks of 500 mg of  decreases ALT levels and hepatic 
steatosis in NAFLD patients 30, and chen et al. demonstrated that 300 mg/d resveratrol 
significantly decreased AST and ALT levels 29,  however, in Chachi et al.'s study, liver enzyme 
levels elevated after 6 weeks of resveratrol supplementation 28. In addition, most animal studies 
have demonstrated that the administration of resveratrol significantly reduced ALT, AST and 
GGT 54,55.These previous outcomes are antithesis, therefore, further high-quality RCTs should be 
done for resolve these discrepancy.
The bases for the beneficial effects of resveratrol on liver function are not totally elucidated but 
the mechanism may involve the following aspects: resveratrol significantly enhanced survival 
after liver transplantation, diminished fat accumulation, necrosis, and apoptosis which induced by 
ischemia in rats. It’s protects the liver from chemical and alcohol injury56. Resveratrol can 
ameliorate glucose homeostasis and lipid metabolism and lessen liver fibrosis and steatosis, in 
fact, in addition to its direct antioxidant effects and reduced ROS production, resveratrol increases 
antioxidant enzymes gene expression and the activity of silent information regulator 2/sirtuin-1 
(Sirt-1) and adenosine monophosphate activated protein kinase (AMP-K), two key factors in 
regulating lipid and glucose metabolism 46. Upregulation of SIRT1 is associated with suppression 
of lipogenic genes expression, improved insulin sensitivity, serum lipid profile and reduced 
steatosis  57. Resveratrol can also reduce inflammation by inhibiting cellular stress, suppressing 
inflammatory gene expression, and enhancing peroxisome receptor-proliferative activity58.
It seems that one of possible reason for the lack of effect of resveratrol on liver enzymes was the 
length of the supplementation period, so that the results of our subgroup analysis showed that 
resveratrol supplementation over longer periods improved the liver enzymes especially ALT and 
AST, so further studies are needed with longer periods in this area. Another possible reason is the 
age of the participants, so the results of the subgroup analysis showed that resveratrol 
supplementation in younger people had a greater effect on liver enzyme levels, especially GGT, 
because older people were considered to be high risk groups. Subgroup analysis also showed that 
resveratrol at a dose of less than 1000 mg significantly reduced GGT levels. In addition, the 
included trials were carried out in study populations with various health conditions, therefore the 
interpretation of the results in this context is complicated.
The present study has a few strengths and limitations. This meta-analysis only includes RCTs and 
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heterogeneity was found among the eligible studies, which may be because of differences in the 
intervention term, study population, sample size and daily dosages of resveratrol. Furthermore, the 
trials included participants with different health conditions, therefore prospective studies in people 
with specific conditions are necessary to achieve definitive results. Also in two studies, the unit of 
measurement of the enzymes was mg / dl which was different from the other (IU/L), so we 
excluded them. In the case of bilirubin and ALP, due to a lack of eligible studies, we could not 
perform subgroup analysis. In addition, we did not register the protocol of the current study on 
PROSPERO registry system due to the delay in processing the submitted protocols for studies 
outside the UK. This lack of registration might be a source of bias for this review. However, this 
review and meta-analysis was designed and performed according to the Cochrane guidelines.
Conclusion
In conclusion, present meta-analysis indicated that resveratrol supplementation had no significant 
effect on liver function tests such as ALT, AST, GGT, ALP and bilirubin.  Further analysis 
indicated that resveratrol supplementation had a greater effect size than the overall outcome in the 
longer term (> 12 week )and younger subjects (age < 48y). However, further well designed, large-
scale studies are needed in the future.
Conflict of interest
The authors declare no conflict of interest.
Acknowledgments
This research was supported by Student Research Committee of Isfahan University of Medical 
Sciences, Isfahan, Iran. 
Author Contribution
E.K and A.Gh wrote the concept, design, and carried out drafting of this study. E.K and A.Gh 
performed searches of the electronic databases, screened the articles and extracted the data. A.H 
performed the acquisition, analysis, and interpretation of data. E.K and A.Gh critically revised the 
manuscript. A.H. performed a final revision and proofread of the article. All authors approved the 










This article is protected by copyright. All rights reserved
This research received specific grant from Student Research Committee, Isfahan University of 










This article is protected by copyright. All rights reserved
References 
1. Rowe IA. Lessons from epidemiology: the burden of liver disease. Digestive diseases. 
2017;35(4):304-309.
2. Xiao J, Wang F, Wong N-K, et al. Global liver disease burdens and research trends: analysis from a 
china perspective. Journal of hepatology. 2019.
3. Neff GW, Duncan CW, Schiff ER. The current economic burden of cirrhosis. Gastroenterology & 
hepatology. 2011;7(10):661.
4. j D. Liver disease pathophysiology. Clinical Pharmacist 2011;3.
5. Muriel P, Rivera-Espinoza Y. Beneficial drugs for liver diseases. Journal of Applied Toxicology: An 
International Journal. 2008;28(2):93-103.
6. Darand M, Alavian SM, Hekmatdoost A. Nigella sativa and non-alcoholic fatty liver disease: a 
review of the current evidence. Hepatitis Monthly. 2018;18(10).
7. Rajaratnam M, Prystupa A, Lachowska-Kotowska P, Zaluska W, Filip R. Herbal medicine for 
treatment and prevention of liver diseases. Journal of Pre-Clinical and Clinical Research. 2014;8(2).
8. Tian B, Liu J. Resveratrol: a review of plant sources, synthesis, stability, modification and food 
application. Journal of the Science of Food and Agriculture. 2020;100(4):1392-1404.
9. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product 
derived from grapes. Science. 1997;275(5297):218-220.
10. Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-
β peptides. Journal of Biological Chemistry. 2005;280(45):37377-37382.
11. Faith SA, Sweet TJ, Bailey E, Booth T, Docherty JJ. Resveratrol suppresses nuclear factor-κB in 
herpes simplex virus infected cells. Antiviral research. 2006;72(3):242-251.
12. Lin J-F, Lin S-M, Chih C-L, et al. Resveratrol reduces infarct size and improves ventricular function 
after myocardial ischemia in rats. Life sciences. 2008;83(9-10):313-317.
13. Zhang F, Liu J, Shi J-S. Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in 
microglial activation. European Journal of Pharmacology. 2010;636(1-3):1-7.
14. Gülçin İ. Antioxidant properties of resveratrol: a structure–activity insight. Innovative Food Science 
& Emerging Technologies. 2010;11(1):210-218.
15. Alarcon De La Lastra C, Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: 










This article is protected by copyright. All rights reserved
16. Nicolini G, Rigolio R, Miloso M, Bertelli AA, Tredici G. Anti-apoptotic effect of trans-resveratrol on 
paclitaxel-induced apoptosis in the human neuroblastoma SH-SY5Y cell line. Neuroscience letters. 
2001;302(1):41-44.
17. Wang B, Sun J, Li X, et al. Resveratrol prevents suppression of regulatory T-cell production, 
oxidative stress, and inflammation of mice prone or resistant to high-fat diet–induced obesity. 
Nutrition research. 2013;33(11):971-981.
18. Gómez-Zorita S, Fernández-Quintela A, Macarulla M, et al. Resveratrol attenuates steatosis in 
obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. British Journal 
of Nutrition. 2012;107(2):202-210.
19. Lee E-S, Shin M-O, Yoon S, Moon J-O. Resveratrol inhibits dimethylnitrosamine-induced hepatic 
fibrosis in rats. Archives of pharmacal research. 2010;33(6):925-932.
20. Shang J, Chen L-l, Xiao F-x, Sun H, Ding H-c, Xiao H. Resveratrol improves non-alcoholic fatty liver 
disease by activating AMP-activated protein kinase. Acta Pharmacologica Sinica. 2008;29(6):698-
706.
21. Hong S-W, Jung KH, Zheng H-M, et al. The protective effect of resveratrol on dimethylnitrosamine-
induced liver fibrosis in rats. Archives of pharmacal research. 2010;33(4):601-609.
22. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and 
meta-analyses: the PRISMA statement. Annals of internal medicine. 2009;151(4):264-269.
23. Higgins J, Altman D, Gøtzsche P, et al. Cochrane bias methods group; cochrane statistical methods 
group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials BMJ. 
2011;343(7829):d5928.
24. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis. John Wiley & 
Sons; 2011.
25. Macedo R, Vieira A, Marin D, Otton R. Effects of chronic resveratrol supplementation in military 
firefighters undergo a physical fitness test–a placebo-controlled, double blind study. Chemico-
biological interactions. 2015;227:89-95.
26. Anton SD, Embry C, Marsiske M, et al. Safety and metabolic outcomes of resveratrol 
supplementation in older adults: results of a twelve-week, placebo-controlled pilot study. 
Experimental gerontology. 2014;57:181-187.
27. Asghari S, Asghari-Jafarabadi M, Somi M-H, Ghavami S-M, Rafraf M. Comparison of calorie-
restricted diet and resveratrol supplementation on anthropometric indices, metabolic 









This article is protected by copyright. All rights reserved
randomized controlled clinical trial. Journal of the American College of Nutrition. 2018;37(3):223-
233.
28. Chachay VS, Macdonald GA, Martin JH, et al. Resveratrol does not benefit patients with 
nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology. 2014;12(12):2092-
2103. e2096.
29. Chen S, Zhao X, Ran L, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism 
in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Digestive and Liver 
Disease. 2015;47(3):226-232.
30. Faghihzadeh F, Adibi P, Hekmatdoost A. The effects of resveratrol supplementation on 
cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-
blind, placebo-controlled study. British Journal of Nutrition. 2015;114(5):796-803.
31. Goh KP, Lee HY, Lau DP, Supaat W, Chan YH, Koh AFY. Effects of resveratrol in patients with type 2 
diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. International 
journal of sport nutrition and exercise metabolism. 2014;24(1):2-13.
32. Heebøll S, Kreuzfeldt M, Hamilton-Dutoit S, et al. Placebo-controlled, randomised clinical trial: 
high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scandinavian journal of 
gastroenterology. 2016.
33. Kantartzis K, Fritsche L, Bombrich M, et al. Effects of resveratrol supplementation on liver fat 
content in overweight and insulin-resistant subjects: A randomized, double-blind, 
placebo-controlled clinical trial. Diabetes, Obesity and Metabolism. 2018;20(7):1793-1797.
34. Kjær TN, Ornstrup MJ, Poulsen MM, et al. No beneficial effects of resveratrol on the metabolic 
syndrome: a randomized placebo-controlled clinical trial. The Journal of Clinical Endocrinology & 
Metabolism. 2017;102(5):1642-1651.
35. Poulsen MM, Vestergaard PF, Clasen BF, et al. High-dose resveratrol supplementation in obese 
men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate 
metabolism, insulin sensitivity, and body composition. Diabetes. 2013;62(4):1186-1195.
36. Pennisi M, Bertino G, Gagliano C, et al. Resveratrol in Hepatitis C Patients Treated with Pegylated-
Interferon-α-2b and Ribavirin Reduces Sleep Disturbance. Nutrients. 2017;9(8):897.
37. Movahed A, Nabipour I, Lieben Louis X, et al. Antihyperglycemic effects of short term resveratrol 











This article is protected by copyright. All rights reserved
38. Seyyedebrahimi S, Khodabandehloo H, Esfahani EN, Meshkani R. The effects of resveratrol on 
markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-
controlled clinical trial. Acta diabetologica. 2018;55(4):341-353.
39. Tomé-Carneiro J, Larrosa M, Yáñez-Gascón MJ, et al. One-year supplementation with a grape 
extract containing resveratrol modulates inflammatory-related microRNAs and cytokines 
expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients 
with coronary artery disease. Pharmacological research. 2013;72:69-82.
40. Mahmood WA, Mshimesh BAR, Khazaal FAK, Jasim SY, Mahmood AA. Potential effects of 
resveratrol on obesity-related nephropathy in Iraqi obese women. Journal of Pharmaceutical 
Sciences and Research. 2018;10(5):999-1005.
41. Queipo-Ortuno MI, Boto-Ordonez M, Murri M, et al. Influence of red wine polyphenols and 
ethanol on the gut microbiota ecology and biochemical biomarkers. The American journal of 
clinical nutrition. 2012;95(6):1323-1334.
42. Bhat KP, Kosmeder JW, Pezzuto JM. Biological effects of resveratrol. Antioxidants and redox 
signaling. 2001;3(6):1041-1064.
43. Donnelly LE, Newton R, Kennedy GE, et al. Anti-inflammatory effects of resveratrol in lung 
epithelial cells: molecular mechanisms. American Journal of Physiology-Lung Cellular and 
Molecular Physiology. 2004;287(4):L774-L783.
44. Wright C, Iyer KV, Yakisich JS, Azad N. Anti-tumorigenic effects of resveratrol in lung cancer cells 
through modulation of c-FLIP. Current cancer drug targets. 2017;17(7):669-680.
45. Lançon A, Frazzi R, Latruffe N. Anti-oxidant, anti-inflammatory and anti-angiogenic properties of 
resveratrol in ocular diseases. Molecules. 2016;21(3):304.
46. Zordoky BN, Robertson IM, Dyck JR. Preclinical and clinical evidence for the role of resveratrol in 
the treatment of cardiovascular diseases. Biochimica et Biophysica Acta (BBA)-Molecular Basis of 
Disease. 2015;1852(6):1155-1177.
47. Brasnyó P, Molnár GA, Mohás M, et al. Resveratrol improves insulin sensitivity, reduces oxidative 
stress and activates the Akt pathway in type 2 diabetic patients. British journal of nutrition. 
2011;106(3):383-389.
48. Fullerton MD, Steinberg GR. SIRT1 takes a backseat to AMPK in the regulation of insulin sensitivity 
by resveratrol. Diabetes. 2010;59(3):551-553.
49. Simental-Mendía LE, Guerrero-Romero F. Effect of resveratrol supplementation on lipid profile in 










This article is protected by copyright. All rights reserved
50. Carrizzo A, Puca A, Damato A, et al. Resveratrol improves vascular function in patients with 
hypertension and dyslipidemia by modulating NO metabolism. Hypertension. 2013;62(2):359-366.
51. Li F, Gong Q, Dong H, Shi J. Resveratrol, a neuroprotective supplement for Alzheimer's disease. 
Current pharmaceutical design. 2012;18(1):27-33.
52. Zhang C, Yuan W, Fang J, et al. Efficacy of resveratrol supplementation against non-alcoholic fatty 
liver disease: A meta-analysis of placebo-controlled clinical trials. PLoS One. 2016;11(8).
53. Elgebaly A, Radwan IA, AboElnas MM, et al. Resveratrol Supplementation in Patients with Non-
Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis. Journal of Gastrointestinal & 
Liver Diseases. 2017;26(1).
54. Tunalı-Akbay T, Sehirli O, Ercan F, Sener G. Resveratrol protects against methotrexate-induced 
hepatic injury in rats. Journal of Pharmacy & Pharmaceutical Sciences. 2010;13(2):303-310.
55. Schmatz R, Perreira LB, Stefanello N, et al. Effects of resveratrol on biomarkers of oxidative stress 
and on the activity of delta aminolevulinic acid dehydratase in liver and kidney of streptozotocin-
induced diabetic rats. Biochimie. 2012;94(2):374-383.
56. Faghihzadeh F, Hekmatdoost A, Adibi P. Resveratrol and liver: A systematic review. Journal of 
research in medical sciences: the official journal of Isfahan University of Medical Sciences. 
2015;20(8):797.
57. Andrade JMO, Paraíso AF, de Oliveira MVM, et al. Resveratrol attenuates hepatic steatosis in high-
fat fed mice by decreasing lipogenesis and inflammation. Nutrition. 2014;30(7-8):915-919.










This article is protected by copyright. All rights reserved
Legends of figures:
Figure 1: Preferred reporting items for systematic reviews and meta-analyses flow diagram of 
study selection process
Figure 2: Forest plot of the effect of resveratrol supplementation on ALT.
Figure 3: Forest plot of the effect of resveratrol supplementation on AST. 
Figure 4: Forest plot of the effect of resveratrol supplementation on GGT. 
Figure 5: Forest plot of the effect of resveratrol supplementation on ALP.
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